Sight OLO
by Sight Diagnostics
· Based in Israel →
— Improving health through fast, accurate and convenient diagnostic testing.
Contact for pricing
Regulatory Status Disclosed
Overview
Sight OLO is an innovative, AI-powered hematology analyzer developed by Sight Diagnostics. It is designed to provide lab-grade complete blood count (CBC) results, including a 5-part differential and 19 parameters, rapidly at the point of care or in clinical laboratories. The compact, desktop device utilizes advanced digital fluorescence microscopy and computer vision algorithms to analyze blood samples. It requires only two drops of blood, obtainable from a finger prick or venous sample, and delivers results in approximately 10 minutes. The system employs single-use, disposable test kits and does not require external reagents or user calibration, simplifying operation and maintenance. Sight OLO is intended for in vitro diagnostic use in screening whole blood samples from children 3 months and above, adolescents, and adults.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI and computer vision for blood analysis
- 19-parameter, 5-part differential CBC
- Uses 2 drops of blood (finger prick or venous)
- Results in 10 minutes
- Compact, desktop device
- Single-use test kits/cartridges, 'dry' instrument
- No external reagents or user calibration required
- Automated fluorescence digital microscopy
- Connectivity to LIS, Middleware, and EPR
- Touchscreen interface
Use Cases
- Complete Blood Count (CBC) testing
- Point-of-care diagnostics
- Screening for anemia, infection, inflammation, bleeding disorders, cancer
- Monitoring oncology patients
- Early triage for infectious diseases (e.g., COVID-19)
- General health evaluation
What Physicians Need to Know
Key Capabilities
Sight OLO is an AI-assisted hematology platform providing a 19-parameter, five-part differential Complete Blood Count (CBC) using advanced computer vision and machine learning algorithms. It accepts both venous and fingerprick blood samples (only 2 drops / 27u00b5L) and delivers lab-grade results in approximately 10 minutes. The compact, tabletop device utilizes single-use test kits, is factory calibrated, and includes a 'Failsafe' self-test system to ensure operational integrity. It also flags specific abnormal white blood cell cases.
Clinical Utility
This tool decentralizes CBC testing, enabling point-of-care use in various settings, including emergency departments, clinics, and hospitals. It aids in rapid diagnosis and monitoring of conditions such as anemia, infections (viral/bacterial differentiation), and oncology patients, allowing for quicker treatment decisions. Its ability to process small, fingerprick samples and provide rapid results is particularly beneficial for patient comfort and in managing contagious samples in quarantined labs, reducing staff exposure.
Integration Options
Sight OLO can transmit results digitally to Laboratory Information Management Systems (LIMS), Electronic Medical Records (EMR), and Electronic Patient Record (EPR) systems. It supports connectivity to middleware like RALS via a direct Ethernet connection, enabling bi-directional communication for patient results, quality control data, operator lists, and device configuration.
Compliance Status
Sight OLO is FDA 510(k) cleared for use in CLIA non-waived settings (moderately complex laboratories) in the United States. It is CE Marked for Point-of-Care (POC) use according to the IVD European directive and has received Health Canada approval for both laboratory and point-of-care settings. It is also listed in the Australian Register of Therapeutic Goods with a point-of-care indication.
Pricing Model
The pricing model is likely based on the purchase of the compact analyzer and recurring costs for single-use test kits. It is designed to be cost-effective in low-volume settings by eliminating the need for liquid reagents, routine maintenance, and calibration, thereby reducing operational expenses.
User Experience
The device features a simple, intuitive touchscreen interface, described as 'iPhone-like', requiring minimal training for operation. The use of small blood volumes (fingerprick or venous) enhances patient comfort. Results are displayed directly on the screen within minutes, with options for printout or digital transmission. It includes a built-in Operator Management feature for access control and traceability.
Support Quality
Sight OLO benefits from remote servicing and an automated internal quality control system, including a 'Failsafe' system, to maintain result integrity. Comprehensive remote training is provided by an Informatics Customer Experience team, and support is available via phone during business hours and online 24/7, especially through RALS connectivity.
Implementation Complexity
Implementation is considered simple due to the device's compact size (approximately one cubic foot, 11kg) and 'dry' operation, eliminating the need for liquid reagents, washouts, or user-performed calibration. An implementation team can quickly integrate the device into existing systems, though an internet connection is required for software updates.
Evidence Base
Sight OLO's performance has been validated in multicenter clinical laboratory settings, demonstrating strong concordance and high accuracy compared to conventional lab analyzers (e.g., Sysmex XN-Series, Unicel DxH800). Clinical trials were conducted at reputable institutions like Boston Children's Hospital and Columbia University Medical Center. The AI algorithms are trained on a vast database of over half a petabyte of blood imagery, and studies have been published in peer-reviewed journals.
Physician Tip
Consider Sight OLO for rapid, lab-grade CBC results directly at the point of care, especially in settings where quick turnaround is critical for patient management, such as emergency departments, oncology clinics, or remote locations. Its ability to use fingerprick samples can improve patient experience and streamline workflows. Leverage its integration capabilities for seamless data flow into EMR/LIS systems to maintain comprehensive patient records and ensure regulatory compliance.
Sight OLO offers robust integration with existing healthcare IT infrastructure, including LIS, EMR, and EPR systems, often through direct Ethernet connectivity and middleware like RALS. This bi-directional communication facilitates automated result transfer, quality control management, and operator credentialing, minimizing manual data entry and enhancing data integrity across the healthcare ecosystem.
Details
| Category | Lab & Diagnostics |
| Pricing | Contact for pricing |
| Deployment | On-premise device for point-of-care or laboratory settings. |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
1 AI-estimated Sight OLO received FDA 510(k) clearance K190898 on November 1, 2019, and a modification clearance K211840 on May 9, 2022, for use in moderately complex laboratories for in vitro diagnostic use in screening capillary or venous whole blood samples to enumerate 19 CBC parameters and a 5-part differential. |
| Integrations | |
| EHR | Not specified |
| Specialties | Emergency Medicine, Hematology, Laboratory Medicine |
What the Web Says
Sight OLO is a compact, lab-grade hematology analyzer designed for point-of-care use, providing complete blood count (CBC) results within minutes from a finger prick of blood. Reviews highlight its ease of use, speed, and accuracy, making it a valuable tool for various clinical settings, though some concerns exist regarding its current test menu limitations and integration with existing EMR systems.
Overall: PositiveStrengths
- Rapid results (minutes) from a finger prick of blood
- Compact and portable design suitable for point-of-care
- User-friendly interface and automated workflow
- High accuracy comparable to central lab analyzers
- Reduces need for venipuncture, improving patient experience
- Potential to streamline clinical decision-making
Limitations
- Limited test menu beyond CBC (e.g., no CRP, ESR)
- Integration with some EMR systems can be challenging or require custom solutions
- Cost of device and consumables may be a factor for smaller practices
- Requires specific training for optimal use, though generally intuitive
- Data management and connectivity could be improved in some instances
- Not yet universally adopted, so familiarity may vary among staff
Based on reviews from: SightDX.com, G2, Capterra, Reddit (r/medlabprofessionals, r/medicine), Healthcare IT News, Medical Device Network
Last updated: 2026-07-19
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate Sight OLO
Press & Coverage
Newswire.ca
Sight Diagnosticsu00ae and Inter Medico Announce the Health Canada Approval of Sight OLO for Point-of-Care Testing
Sight Diagnostics received Health Canada approval for its Sight OLO analyzer for point-of-care settings, expanding its reach in Canada for rapid, 5-part differential Complete Blood Count (CBC) testing from a finger prick sample. This approval allows for decentralized testing in various healthcare settings, including small rural hospitals and clinics.
2022-01
Medical Buyer
Sight Diagnostics lays off all employees, shut down sword looms large - Medical Buyer
Sight Diagnostics has reportedly laid off all of its approximately 20 remaining employees, with a potential shutdown looming. The company, which developed the Sight OLO device for rapid complete blood count tests, has undergone a series of layoffs and organizational changes in recent years.
2026-04
Ctech
Blood testing startup Sight Diagnostics lays off 30% of team | Ctech
Sight Diagnostics laid off approximately 30% of its workforce, around 40 employees, marking its second significant round of layoffs. The company, which developed the Sight OLO blood count device, cited the challenging macroeconomic reality as the reason for the adjustments.
2024-05
PMC (American Journal of Hematology)
An artificial intelligenceu2010assisted diagnostic platform for rapid nearu2010patient hematology
This peer-reviewed study evaluates the Sight OLO, an AI-assisted hematological platform providing a 19-parameter, five-part differential CBC. The study found strong concordance between OLO and the Sysmex XN, a gold standard analyzer, demonstrating high accuracy and repeatability for all CBC parameters using venous, capillary, and fingerprick blood samples.
2021-10
Dark Daily
Oxford University Hospital Deploys Sight Olo Analyzer for Covid Screening
Sight Diagnostics deployed its Sight OLO analyzer at John Radcliffe Hospital, part of the Oxford University Hospitals NHS Foundation Trust, for rapid full blood count (FBC) testing. This deployment supports the validation of a rapid AI triage system for COVID-19, aiming to provide accurate predictions in under 30 minutes.
2021-03
Business Wire
Sight Diagnostics Raises $71M To Accelerate Global Expansion of its FDA 510(k) Cleared, CE Marked Finger-prick Blood Analyzer
Sight Diagnostics announced a $71 million Series D funding round to accelerate the global expansion of its Sight OLO analyzer, which provides lab-grade CBC results from a fingerstick or venous sample. The funding will support expanding its U.S. footprint and advancing R&D for detecting additional diseases and COVID-19 biomarkers.
2020-08
The Times of Israel
Israeli blood test startup Sight Diagnostics inks deal for distribution in UAE
Sight Diagnostics signed a distribution partnership with Dubai-based Phoenix Capital to install its OLO blood analyzer machines in nine medical centers in the UAE, with plans to expand into other Gulf regions, including Saudi Arabia. The deal aims to address the need for on-site, point-of-care testing in the region.
2020-12
Fierce Biotech
Sight Diagnostics' finger prick blood tester wins FDA clearance - Fierce Biotech
Sight Diagnostics received FDA 510(k) clearance for its OLO analyzer, allowing it to provide lab-grade complete blood count (CBC) results from a finger prick in minutes for use in hospitals and clinics. The device uses digital microscopes and is commercially available in Europe and other international markets.
2019-12
Videos
Product demos, reviews, and walkthroughs for Sight OLO.
Sight Diagnostics OLO Hematology Analyzer for Complete Blood Count
Frequently Asked Questions
Sight OLO is a compact, AI-powered hematology analyzer designed for point-of-care (POC) and near-patient settings. It provides a 19-parameter, five-part differential Complete Blood Count (CBC), which is comparable to lab-grade results.
Clinical studies have demonstrated that Sight OLO performs with high accuracy and strong concordance when compared to central lab hematology analyzers, such as the Sysmex XN-Series. It delivers lab-grade results, including enumeration of low cell counts, across a wide variety of patient samples.
Sight OLO accepts both venous and fingerprick blood samples, requiring only two drops (27 u00b5L) for a fingerprick test. Results for a full CBC are typically available within minutes, often around 10 minutes, directly on the device's touchscreen.
In the United States, Sight OLO has received FDA 510(k) clearance for use in moderately complex laboratory settings. It is CE marked for point-of-care use in Europe, including direct-from-fingerprick samples, and has Health Canada approval for POC settings.
Integrating Sight OLO allows for rapid, on-site CBC testing, enabling quicker clinical decision-making and potentially reducing patient follow-up visits. The device is low maintenance, factory-calibrated, and uses disposable cartridges, eliminating the need for reagent management or liquid waste disposal.
While Sight OLO is cleared for use in children aged 3 months and above, adolescents, and adults, its FDA clearance in the US is currently for moderately complex laboratory settings, not CLIA-waived point-of-care. Although studies show excellent performance in enumerating low platelet counts, the established analytical measurement range for platelets is technically limited at the lower end.
The Sight OLO analyzer itself can range from approximately $4,500 to $5,250 for the device. It is designed to be cost-effective for point-of-care use, especially in low-volume settings, and utilizes single-use test kits, implying a per-test cost for consumables.
Suggest an Edit →
| Last Verified: 2026-04-19 | First Added: 2026-04-19
Investors who backed Sight OLO
Funded through the company that built this tool.
